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In the title compound, C24H19ClN2O3S, the sulfonyl-bound
benzene ring forms dihedral angles of 38.1 (2) and 81.2 (1) ,
respectively, with the formyl benzene and benzene rings. The
molecular conformation is stabilized by a weak intramolecular
C—H   O hydrogen bond, which generates an S(5) ring motif.
The crystal packing is stabilized by C—H   O hydrogen
bonds, which generate C(7) zigzag chains along [010] and
R3
3(19) ring motifs along [010]. The crystal packing is further
stabilized by C—Cl     interactions [Cl   centroid =
3.456 (2) A ˚ and C—Cl   centroid = 173.4 (2) ].
Related literature
For background to the pharmacological uses of sulfonamides,
see: Korolkovas (1988); Mandell & Sande (1992). For related
structures, see: Ranjith et al. (2009); Aziz-ur-Rehman et al.






a = 8.9795 (5) A ˚
b = 10.1590 (5) A ˚
c = 25.1050 (13) A ˚
V = 2290.1 (2) A ˚ 3
Z =4
Mo K  radiation
  = 0.29 mm
 1
T = 293 K






Tmin = 0.931, Tmax = 0.953
12721 measured reﬂections
4850 independent reﬂections












 max = 0.22 e A ˚  3
 min =  0.21 e A ˚  3
Absolute structure: Flack (1983),
2049 Friedel pairs
Flack parameter: 0.06 (8)
Table 1
Hydrogen-bond geometry (A ˚ ,  ).
D—H   AD —H H   AD    AD —H   A
C15—H15A   O3 0.97 2.43 2.890 (3) 109
C3—H3   O2
i 0.93 2.57 3.345 (3) 141
C15—H15A   O2
ii 0.97 2.57 3.385 (3) 142
C23—H23   O1
iii 0.93 2.45 3.114 (4) 128
Symmetry codes: (i)  x þ 2;y þ 1
2; z þ 1
2; (ii)  x þ 1;y þ 1
2; z þ 1
2; (iii) x;y þ 1;z.
Data collection: APEX2 (Bruker, 2004); cell reﬁnement: APEX2
and SAINT (Bruker, 2004); data reduction: SAINT and XPREP
(Bruker, 2004); program(s) used to solve structure: SHELXS97
(Sheldrick, 2008); program(s) used to reﬁne structure: SHELXL97
(Sheldrick, 2008); molecular graphics: ORTEP-3 (Farrugia, 1997;
software used to prepare material for publication: SHELXL97 and
PLATON (Spek, 2009).
The authors thank Dr Babu Vargheese, SAIF, IIT, Madras,
India, for his help with the data collection.
Supplementary data and ﬁgures for this paper are available from the
IUCr electronic archives (Reference: BT5740).
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